GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (MEX:ZLAB N) » Definitions » Institutional Ownership

Zai Lab (MEX:ZLAB N) Institutional Ownership : 32.85% (As of Jul. 18, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Zai Lab Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zai Lab's institutional ownership is 32.85%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zai Lab's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zai Lab's Float Percentage Of Total Shares Outstanding is 0.00%.


Zai Lab Institutional Ownership Historical Data

The historical data trend for Zai Lab's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Institutional Ownership Chart

Zai Lab Historical Data

The historical data trend for Zai Lab can be seen below:

2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30 2025-05-31 2025-06-30
Institutional Ownership 39.56 42.92 42.58 41.19 41.03 41.66 36.59 34.64 33.89 32.85

Zai Lab Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Zai Lab Business Description

Traded in Other Exchanges
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Zai Lab Headlines

No Headlines